Dr. Lahn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2475 Saint Raymonds Ave
Bronx, NY 10461Phone+1 718-430-7350Fax+1 718-828-5783
Education & Training
- Montefiore Medical Center/Albert Einstein College of Medicine (Jacobi/Montefiore)Residency, Emergency Medicine, 1994 - 1997
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1990 - 1993
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1990
Certifications & Licensure
- NY State Medical License 1991 - 2025
- CT State Medical License 2016 - 2019
- American Board of Emergency Medicine Emergency Medicine
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Publications & Presentations
PubMed
- 94 citationsNovel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinomaSandrine Faivre, Armando Santoro, Robin Kate Kelley, Edward Gane, Charlotte Costentin
Liver International. 2019-08-01 - 58 citationsTGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancerDavide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque
Cancer Chemotherapy and Pharmacology. 2019-03-18 - 191 citationsGalunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque
British Journal of Cancer. 2018-10-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: